Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 12, 2026 · Filed Nov 16, 2026
Merck's &Pres, Merck Animal Heallth sold $8.61M of Merck shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$8,611,875
Shares × reported transaction price
14 days after results of Oct 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $146.95 on Nov 12, 2026, 58% above its 52-week low and 6% below its high, after a 2% rise over the previous 30 trading days
52-week range $92.86 (Nov 17, 2025) to $156.45 (Aug 25, 2026), 85% of the way up, from 251 adjusted closes. 30 trading days earlier: $143.81 on Oct 1, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Keytruda on Oct 16, 2026, 27 days before this trade.
New use approved (efficacy supplement). Active ingredient: Pembrolizumab. From openFDA. Dates only; no link between the two is implied
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Nov 12 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 12 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.